Nebula Genomics, a blockchain firm has announced its collaboration with EMD Serono. Merck KGaA’s is called the biopharmaceutical business of EMD Serono. Merck KGaA is a German multinational pharmaceutical, chemical and life sciences company. Merck is also the oldest operating chemical and pharmaceutical company. This year, in January Merck was awarded a patent in the US for a system that uses a combination of AI (Artificial Intelligence) and blockchain technology to identify the authenticity of unique physical objects.
Co-founded in the year 2017 by a well-renowned geneticist, Prof. George Church, and his colleagues Dennis Grishin and Kamal Obbad, Nebula is blockchain powered platform for genome-sequencing data. Nebula’s collaboration with EMD Serono will provide the firm with access to its network of anonymized genomic data so that research and development of new medicines will be given strong support. This blockchain powered platform influences blockchain technology in a bid to encourage genomic data generation as well as sharing while lowering the cost of genome sequencing and preserving privacy and control over sensitive and unique data. Slow data generation, data fragmentation, and inefficient consent management form barriers to realizing the transformative potential that genomic datasets hold for healthcare and biomedical research. Major pharmaceutical firm Boehringer Ingelheim recently partnered with Solve.Care, a blockchain healthcare platform. Boehringer Ingelheim partnered with the blockchain healthcare platform with an aim to build a blockchain and digital asset-powered network for trusted sharing of data of diabetic patients.